Stoke Therapeutics (NASDAQ:STOK) Shares Up 8.2% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares rose 8.2% on Tuesday . The stock traded as high as $12.85 and last traded at $12.46. Approximately 346,900 shares traded hands during trading, a decline of 58% from the average daily volume of 827,714 shares. The stock had previously closed at $11.52.

Wall Street Analyst Weigh In

STOK has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Stock Up 9.5 %

The business has a fifty day moving average price of $11.07 and a 200 day moving average price of $12.65. The company has a market capitalization of $667.90 million, a P/E ratio of -6.02 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. As a group, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares in the company, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 in the last ninety days. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in Stoke Therapeutics by 528.6% during the 2nd quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after purchasing an additional 243,083 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth about $192,000. Los Angeles Capital Management LLC lifted its stake in shares of Stoke Therapeutics by 54.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after purchasing an additional 36,240 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $160,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.